Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models

Crizotinib [Xalkori; PF02341066; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine] is an orally available dual inhibitor of anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor. The objectives of the present studies were to characterize: 1) the pharmacokinetic/pharmacodynamic relationship of crizotinib plasma concentrations to the inhibition of ALK phosphorylation in tumors, and 2) the relationship of ALK inhibition to antitumor efficacy in human tumor xenograft models. Crizotinib was orally administered to athymic nu/nu mice implanted with H3122 non–small-cell lung carcinomas or severe combined immunodeficient/beige mice implanted with Karpas299 anaplastic large-cell lymphomas. Plasma concentration-time courses of crizotinib were adequately described by a one-compartment pharmacokinetic model. A pharmacodynamic link model reasonably fit the time courses of ALK inhibition in both H3122 and Karpas299 models with EC50 values of 233 and 666 ng/ml, respectively. A tumor growth inhibition model also reasonably fit the time course of individual tumor growth curves with EC50 values of 255 and 875 ng/ml, respectively. Thus, the EC50 for ALK inhibition approximately corresponded to the EC50 for tumor growth inhibition in both xenograft models, suggesting that >50% ALK inhibition would be required for significant antitumor efficacy (>50%). Furthermore, based on the observed clinical pharmacokinetic data coupled with the pharmacodynamic parameters obtained from the present nonclinical xenograft mouse model, >70% ALK inhibition was projected in patients with non–small-cell lung cancer who were administered the clinically recommended dosage of crizotinib, twice-daily doses of 250 mg (500 mg/day). The result suggests that crizotinib could sufficiently inhibit ALK phosphorylation for significant antitumor efficacy in patients.

[1]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[2]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[3]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[4]  Steven P Gygi,et al.  Signaling networks assembled by oncogenic EGFR and c-Met , 2008, Proceedings of the National Academy of Sciences.

[5]  J. Engelman,et al.  Acquired resistance to tyrosine kinase inhibitors during cancer therapy. , 2008, Current opinion in genetics & development.

[6]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[7]  Vikram Sinha,et al.  Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation , 2005, The AAPS Journal.

[8]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[9]  U. McDermott,et al.  Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. , 2010, Cancer research.

[10]  Mats O. Karlsson,et al.  Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[13]  A. Rowan.  Guide for the Care and Use of Laboratory Animals , 1979 .

[14]  P. Ma,et al.  Clinical development of MET targeted therapy for human cancer , 2009 .

[15]  Jeffrey W. Clark,et al.  Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. , 2010 .

[16]  Shinji Yamazaki,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models , 2008, Drug Metabolism and Disposition.

[17]  M. Hollingshead,et al.  Antitumor efficacy testing in rodents. , 2008, Journal of the National Cancer Institute.

[18]  Francesca Demichelis,et al.  EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.

[19]  L B Sheiner,et al.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. , 1984, Drug metabolism reviews.

[20]  Shinji Yamazaki,et al.  Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model , 2011, Drug Metabolism and Disposition.

[21]  Hartmut Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development , 2000, Journal of clinical pharmacology.

[22]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[23]  R. Weichselbaum,et al.  Predictors of competing mortality in advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Shinji Yamazaki,et al.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.

[25]  L. Kèlland,et al.  Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. , 2004, European journal of cancer.

[26]  J. Kutok,et al.  Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Fukamizu,et al.  Expressions of Cytochrome P450, UDP-Glucuronosyltranferase, and Transporter Genes in Monolayer Carcinoma Cells Change in Subcutaneous Tumors Grown As Xenografts in Immunodeficient Nude Mice , 2010, Drug Metabolism and Disposition.

[28]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[29]  H. Mano.  Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer , 2008, Cancer science.

[30]  S. Burchill.  What do, can and should we learn from models to evaluate potential anticancer agents? , 2006, Future oncology.

[31]  V. Mody,et al.  International Society for the Study of Xenobiotics , 2019, Reference Module in Biomedical Sciences.

[32]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[33]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[34]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[35]  Shinji Yamazaki,et al.  An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.

[36]  J. Christensen,et al.  Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). , 2011, Journal of medicinal chemistry.

[37]  N. Spector.  Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab. , 2008, Clinical breast cancer.

[38]  R. Salgia,et al.  MET receptor tyrosine kinase. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[40]  Jeffrey W. Clark,et al.  Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  T. Fojo,et al.  Mitosis is not a key target of microtubule agents in patient tumors , 2011, Nature Reviews Clinical Oncology.